ArticleFrontiers in oncology2020
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Association of TERT promoter mutation with oral squamous cell carcinoma: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- An Accessible Approach to Molecular and Biomarker Testing for Risk Stratification in Oral Cavity Squamous Cell Carcinoma.Head and neck pathology · 2026Article
- Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Molecular insight into Proliferative Verrucous Leukoplakia: Are TERT promoter mutations a predictive marker?Virchows Archiv : an international journal of pathology · 2026Article
- Barnaculate Carcinoma in Four Patients: Verrucoid Squamous Cell Carcinoma Subtype with TERT and HRAS Oncogenic Variants.Head and neck pathology · 2026Article
- Quantifying TERT promoter mutations in tumor-derived DNA shed into the oral cavity as a potential biomarker for oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- IntratumoralJournal of oral microbiology · 2025Article
- Epithelial‑derived head and neck squamous tumourigenesis (Review).Oncology reports · 2024Review
- Upregulation of Apoptosis Related Genes in Clinically Normal Tongue Contralateral to Squamous Cell Carcinoma of the Oral Tongue, an Effort to Maintain Tissue Homeostasis.Head and neck pathology · 2024Article
- Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.Frontiers in oncology · 2024Article
- Atypical Case of Highly Mutated h-TERT Promoter in Germline Genome from Buccal Mucosa Cancer.Indian journal of clinical biochemistry : IJCB · 2023Article
- Transcriptional analysis links B cells and TERT expression to favorable prognosis in head and neck cancer.PNAS nexus · 2023Article
- Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer.Biomedicines · 2023Review
- TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic Apoptosis.Biology · 2022Article
- Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Squamous Cell Carcinomas IdentifiesFrontiers in oncology · 2022Article
- Construction of Molecular Subtype and Prognosis Prediction Model of Osteosarcoma Based on Aging-Related Genes.Journal of oncology · 2022Article
- Arecoline Is Associated With Inhibition of Cuproptosis and Proliferation of Cancer-Associated Fibroblasts in Oral Squamous Cell Carcinoma: A Potential Mechanism for Tumor Metastasis.Frontiers in oncology · 2022Article
- Article
- Article
- Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.Journal of neuro-oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.